每年專案
個人檔案
學歷
- 1996 美國約翰霍普金斯大學公共衛生（健康政策與管理學）博士
- 1987 台灣大學國際貿易學系學士
經歷
- 2007 臺北醫學大學醫務管理學系教授
- 1997 臺北醫學大學醫務管理學系副教授
研究興趣
- 健康經濟學
- 經濟評估
指紋
查看啟用 Chao-Hsiun Tang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 9 類似的個人檔案
網路
國家層面的近期外部共同作業。通過按一下圓點深入探索詳細資料。
專案
- 14 已完成
研究成果
-
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan
Liu, Y., Tang, C-H., Qiu, H., Siggins, S. & Hou, H-A., 一月 13 2021, 於: Scientific Reports. 11, 1, p. 1112研究成果: 雜誌貢獻 › 文章 › 同行評審
1 引文 斯高帕斯（Scopus） -
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan
Liu, Y., Hou, H-A., Qiu, H. & Tang, C-H., 九月 1 2020, 於: Scientific Reports. 10, 1, p. 14393研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Prevalence of baseline comorbidities in patients with atopic dermatitis: A population-based cohort study in Taiwan
Cho, Y-T., Hsieh, W-T., Chan, T. C., Tang, C-H. & Chu, C-Y., 2020, 於: JAAD International. 1, 1, p. 50-58 9 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Treatment evolution and improved survival in multiple myeloma in Taiwan
Tang, C. H., Hou, H. A., Huang, K. C., Qiu, H. & Liu, Y., 二月 1 2020, 於: Annals of Hematology. 99, 2, p. 321-330 10 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取5 引文 斯高帕斯（Scopus） -
Comparison of healthcare utilization and costs between RA patients receiving biological and conventional synthetic DMARDs: A nationwide population-based cohort study in Taiwan
Chen, D. Y., Yu, F., Tuan, L. W. & Tang, C. H., 一月 1 2019, 於: Frontiers in Pharmacology. 10, 1214.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取2 引文 斯高帕斯（Scopus）
資料集
-
Protein-energy wasting significantly increases healthcare utilization and costs among patients with chronic kidney disease: a propensity-score matched cohort study
Chao, C. (Contributor), Tang, C. (Contributor), Cheng, R. W. (Contributor), Wang, M. Y. (Contributor) & Hung, K. (Contributor), Unknown Publisher, 九月 2 2017
DOI: 10.6084/m9.figshare.5198317.v1, https://tandf.figshare.com/articles/figure/Protein-energy_wasting_significantly_increases_healthcare_utilization_and_costs_among_patients_with_chronic_kidney_disease_a_propensity-score_matched_cohort_study/5198317/1
資料集: Dataset
-
A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study
Chiu, Y. (Contributor), Tang, C. (Contributor), Hung, S. (Contributor), Yang, Y. (Contributor), Fang, C. (Contributor) & Lin, H. (Contributor), Unknown Publisher, 五月 4 2017
DOI: 10.6084/m9.figshare.4047471.v1, https://tandf.figshare.com/articles/journal_contribution/A_real-world_risk_analysis_of_biological_treatment_adalimumab_and_etanercept_in_a_country_with_a_high_prevalence_of_tuberculosis_and_chronic_liver_disease_a_nationwide_population-based_study/4047471/1
資料集: Dataset
-
Factors affecting discontinuation of adalimumab and etanercept therapy in anti-TNF-naïve patients with ankylosing spondylitis: Nationwide population-based cohort study
Chen, H. (Contributor), Chen, Y. (Contributor), Lai, K. (Contributor), Lin, C. (Contributor), Tang, C. (Contributor) & Chen, D. (Contributor), Unknown Publisher, 九月 8 2015
DOI: 10.6084/m9.figshare.1601856.v1, https://tandf.figshare.com/articles/journal_contribution/Factors_affecting_discontinuation_of_adalimumab_and_etanercept_therapy_in_anti_TNF_na_239_ve_patients_with_ankylosing_spondylitis_Nationwide_population_based_cohort_study/1601856/1
資料集: Dataset